Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma [Phase 2]
A Phase 2 safety study evaluating lenalidomide maintenance after allogeneic hematopoietic cell transplantation in high-risk multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2014-04-04Clinical Trial Update: Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial evaluating dexamethasone with or without thalidomide in newly diagnosed multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2014-04-02Clinical Trial Update: Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating busulfan and cyclophosphamide with autologous stem cell transplant in multiple myeloma has completed with …
-
CLINICAL_TRIALS trial_result · 2014-03-24Clinical Trial Update: Oligosecretary Myeloma: Prevalence and Its Clinical Significance
A completed study from Samsung Medical Center investigates the prevalence of oligosecretory myeloma and its clinical significance.
-
CLINICAL_TRIALS trial_result · 2014-03-21Clinical Trial Update: Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant [Phase 1]
Phase 1 trial evaluating vaccine therapy with or without donor lymphocyte infusion in patients with acute myeloid leukemia, acute lymphoblas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-03-21Clinical Trial Update: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma [Phase 2]
A Phase 2 study evaluating second-line regimens PAD (bortezomib, doxorubicin, dexamethasone) or vincristine-doxorubicin-dexamethasone in mul…
-
CLINICAL_TRIALS trial_result · 2014-03-07Clinical Trial Update: Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy plus biological therapy followed by peripheral stem cell transplantation for hematologic ca…
-
CLINICAL_TRIALS trial_result · 2014-03-07Clinical Trial Update: Thalidomide to Patients With Previously Untreated Multiple Myeloma [Phase 3]
Phase 3 clinical trial update on thalidomide in patients with previously untreated multiple myeloma; the study status is reported as complet…
-
CLINICAL_TRIALS trial_result · 2014-03-04Clinical Trial Update: Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) [Phase 3]
Phase III randomized trial in multiple myeloma comparing thalidomide/dexamethasone vs vincristine/adriamycin/dexamethasone was terminated wi…
-
CLINICAL_TRIALS trial_result · 2014-03-03Clinical Trial Update: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy [Phase 2]
Phase 2 trial evaluating the combination of bortezomib, cyclophosphamide, and dexamethasone in untreated multiple myeloma patients planned f…
-
CLINICAL_TRIALS trial_result · 2014-02-28Clinical Trial Update: Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse [Phase 1]
Phase 1 study evaluating the safety, anti-tumor activity, and pharmacology of IPH2101 in combination with lenalidomide in patients with mult…
-
CLINICAL_TRIALS trial_result · 2014-02-25Clinical Trial Update: Agaricus Blazei Murill in Patients With Multiple Myeloma [Phase 2]
A phase 2 clinical trial evaluating Agaricus blazei Murill extract in patients with multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). [Phase 2]
A Phase 2 trial evaluated the safety and efficacy of adding AMD3100 to a G-CSF mobilization regimen in patients with non-Hodgkin lymphoma, H…
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only [Phase 3]
Phase 3 open-label extension updates for skeletal-related events in patients with bone metastases from prostate cancer and breast cancer (an…
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) [Phase 1, Phase 2]
Clinical trial GS-9219 in chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma (Phase 1/2) has been terminated.
-
CLINICAL_TRIALS trial_result · 2014-01-27Clinical Trial Update: A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma [Phase 1]
A Phase 1 dose-escalation study sponsored by AVEO Pharmaceuticals in patients with advanced lymphomas and multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma [Phase 3]
Phase 3 clinical trial evaluating lenalidomide and dexamethasone with or without thalidomide in patients with multiple myeloma (stages I–III…
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating lenalidomide and dexamethasone with or without thalidomide for multiple myeloma; results posted in 2014 with active…
-
CLINICAL_TRIALS trial_result · 2014-01-20Clinical Trial Update: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) [Phase 1, Phase 2]
This update reports results from a phase 1/2 study evaluating the CVDD combination (cyclophosphamide, bortezomib, liposomal doxorubicin, and…
-
CLINICAL_TRIALS trial_result · 2014-01-16Clinical Trial Update: Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 clinical trial of brostallicin for recurrent or refractory multiple myeloma and related plasma cell neoplasms has completed enroll…
-
CLINICAL_TRIALS trial_result · 2014-01-14Clinical Trial Update: VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
A post-authorization study (VALEO) update evaluating the safety and effectiveness of bortezomib in the Netherlands has completed.
-
CLINICAL_TRIALS trial_result · 2014-01-10Clinical Trial Update: Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update on phase 1/2 testing of stem cell transplant, chemotherapy, and biological therapy in high-risk or refractory multiple…
-
CLINICAL_TRIALS trial_result · 2014-01-08Clinical Trial Update: Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating arsenic trioxide (Trisenox), ascorbic acid, and bortezomib in relapsed/refractory multiple myeloma has been termina…
-
CLINICAL_TRIALS trial_result · 2014-01-06Clinical Trial Update: Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma [Phase 2]
Phase 2 trial evaluating a combination of Granulocyte Colony-Stimulating Factor, Bortezomib, Cyclophosphamide, and Dexamethasone in patients…
-
CLINICAL_TRIALS trial_result · 2014-01-06Clinical Trial Update: Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating dexamethasone with or without oblimersen for relapsed or refractory multiple myeloma has completed.